title: Prognostic factors influencing feasibility of cytogenetic and molecular analysis in leukapheresis products in chronic myelogenous leukemia patients.
abstract: Conventional cytogenetic (CC) study and molecular analysis were performed in 150 leukapheresis products from 36 patients diagnosed with chronic myelogenous leukemia who were included in an autologous stem cell transplantation program. The aims of the study were to evaluate the effectiveness of these two methods for the detection of residual disease in the harvest and to identify the factors influencing the number of cycling cells present in the apheresis products. Progenitor cell mobilization procedures performed late after diagnosis (>12 months), a short interval between interferon-alpha discontinuation and mobilization (<3.5 months), and an intensive mobilization regimen (idarubicin, cytarabine, and etoposide, ICE protocol) were associated with a low probability of obtaining 25 metaphases, which was achieved in only 41 instances (25% of the samples). In 38 samples, less than ten metaphases were obtained; a peripheral blood leukocyte count <1.0x10(9)/l at mobilization and mononuclear cell counts in the bag <0.5x10(8)/kg significantly increased the probability to obtain less than ten metaphases for CC analysis. Previous interferon-alpha treatment during > or =12 months and low mononuclear cell counts in the bag (<0.5x10(8)/kg) increased the probability of not obtaining mitosis for cytogenetic analysis. Molecular analysis by the polymerase chain reaction (PCR) technique did not give discriminate information in the samples not evaluable by cytogenetics due to the high frequency of PCR-positive results. We conclude that new techniques such as hypermetaphase fluorescence in situ hybridization (FISH), interphase FISH, or quantitative PCR need to be routinely employed in the study of leukapheresis samples of chronic myelogenous leukemia patients for a better assessment of the neoplastic contamination of the infused products.
authors.affiliation: Department of Hematology, Hospital de la Santa Creu i Sant Pau, St. Antoni Maria i Claret, 167, Autonomous University of Barcelona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Carrasco
authors.forename: A
authors.initials: A
authors.lastname: Sureda
authors.forename: C
authors.initials: C
authors.lastname: Martínez
authors.forename: M
authors.initials: M
authors.lastname: Carmona
authors.forename: A
authors.initials: A
authors.lastname: Altés
authors.forename: G A
authors.initials: GA
authors.lastname: Martín-Henao
authors.forename: A
authors.initials: A
authors.lastname: Aventín
authors.forename: J
authors.initials: J
authors.lastname: Sierra
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology; D020732:Cytogenetic Analysis / Q000592:standards*; D005240:Feasibility Studies; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D006801:Humans; D007937:Leukapheresis / Q000592:standards*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000628:therapy*; D008297:Male; D008677:Metaphase; D008875:Middle Aged; D025202:Molecular Diagnostic Techniques / Q000379:methods / Q000592:standards*; D018365:Neoplasm, Residual / Q000175:diagnosis; D009360:Neoplastic Cells, Circulating; D036102:Peripheral Blood Stem Cell Transplantation; D011379:Prognosis; D014182:Transplantation, Autologous